Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 8 of 8 entries
View as:

A Phase 1/2 Study of AEB1102 in Patients With Arginase I Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT02488044 Org: User:
Start: 06/30/16 End: 02/28/19 Due: 02/28/20

A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS

Phase: N/A Priority: Normal
NCT ID: NCT02732184 Org: User:
Start: 08/31/16 End: 12/31/17 Due: 12/31/18

A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02561234 Org: User:
Start: 10/31/15 End: 05/31/19 Due: 05/31/20

A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT05676853 Org: User:
Start: 04/04/23 End: 04/27/23 Due: 04/27/24

A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT03378531 Org: User:
Start: 12/07/17 End: 12/15/22 Due: 12/15/23

Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03371979 Org: User:
Start: 12/21/17 End: 01/01/21 Due: 01/01/22

A Multiple Ascending Dose Study of ACN00177 (Pegtarviliase) in Subjects With CBS Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT05154890 Org: User:
Start: 05/13/21 End: 04/21/23 Due: 04/21/24

Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT03921541 Org: User:
Start: 04/10/19 End: 01/27/23 Due: 01/27/24